What the FDA labels say about taking them together
Cyclosporine and rifaximin
Rifaximin's FDA label of June 25, 2025 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name rifaximin. The rifaximin label: “Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the rifaximin FDA label on DailyMed (effective June 25, 2025, Salix Pharmaceuticals, Inc.).
What does the cyclosporine label say about rifaximin?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name rifaximin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the rifaximin label say about cyclosporine?
Rifaximin label, drug interactionsConcomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin.
Rifaximin label, warnings and precautionsConcomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed.
Source: FDA drug label (XIFAXAN), Salix Pharmaceuticals, Inc., effective June 25, 2025 (SPL set c5e8e2fd-7087-4b78-9181-cc259c0be2f1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Rifaximin | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Diarrhea, Irritable bowel syndrome |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once